Health Benefits of Whole-body Vibration

This study is looking into the health benefits of Whole-body Vibration (WBV). Researchers want to see if using a personal vibration plate at home can improve your exercise ability, blood vessel function, and muscle function. You would use a vibration plate for 10 minutes a day, 3-4 days a week, for 12 weeks. The study aims to understand if WBV can help reduce the risk of heart disease, especially in people with conditions like diabetes or obesity. They will measure changes in your exercise capacity (VO2 Peak), blood vessel health (Flow-Mediated Dilation or FMD), and muscle function. The study is currently unclear on its recruitment status. You may be able to join if you are 18 years or older, but you cannot participate if you have certain heart, liver, or kidney diseases, diabetic complications, are pregnant, or take certain medications that affect blood vessels.

Study design
This is an interventional study planning to enroll 40 participants. It is not specified if it is randomized or blinded.
What's involved
You would use a personal vibration plate at home for 12 weeks. For the first four weeks, you'd do 10 minutes of WBV per day (1 minute on, up to 1 minute rest), at least 3-4 days per week. Measurements will be taken at the start and after 12 weeks.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 12 weeks, with measurements taken at baseline and after the 12-week intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05097885

Health Benefits of Whole-body Vibration

Recruiting
NAAges 18+InterventionalTreatment
Augusta University
~40 participants
Updated 2025-01-28 on ClinicalTrials.gov
What's tested:Sub Acute Whole Body Vibration Training

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in VO2 Peak
Measured over pre-treatment baseline and following 12 weeks sub-acute whole-body vibration
+5 more outcomes measured
Whole-body Vibration

NCT05097885

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Augusta University/Georgia Prevention Institute/ Laboratory of Integrative and Exercise Physiology

    Augusta, Georgiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Men and women (\> 18 yrs old)
All races

Exclusion

\<18 years old
Clinical diagnosis of hepatic, cardiovascular, or renal disease
Diabetic complications (i.e. macrovascular, microvascular, or autonomic)
Pregnancy
Direct vasoactive medications (i.e. nitrates)
  • Change in VO2 Peakpre-treatment baseline and following 12 weeks sub-acute whole-body vibration

    change from baseline relative (mL/kg/min) peak oxygen consumption (VO2) during maximal exercise test at 12 weeks

  • Change in Flow-Mediated Dilation (FMD)pre-treatment baseline and following 12 weeks sub-acute whole-body vibration

    change from baseline brachial artery flow mediated dilation at 12 weeks.

  • Change in Skeletal Muscle Mitochondrial Functionpre-treatment baseline and following 12 weeks sub-acute whole-body vibration

    change from baseline skeletal muscle mitochondrial function at 12 weeks. Measured using Near Infrared Spectroscopy (NIRS). Values are an index of phosphocreatine recovery expressed as a rate constant (min-1)

  • Change in Pulse Wave Velocity (PWV)pre-treatment baseline and following 12 weeks sub-acute whole-body vibration

    Change from baseline PWV at 12 weeks. Measured by Shygmocor Xcel in m/s.

  • Change in Post Occlusive Reactive Hyperemia (PORH)pre-treatment baseline and following 12 weeks sub-acute whole-body vibration

    Change from baseline PORH at 12 weeks. Measured by Laser Speckle Contrast Imager (Moor FLPI).

  • Change in IL-6pre-treatment baseline and following 12 weeks sub-acute whole-body vibration

    change from baseline concentrations of Interleukin 6 (IL-6) obtained via blood draw at 12 weeks.